Tags

Type your tag names separated by a space and hit enter

Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
Thromb Haemost 1999; 81(2):229-33TH

Abstract

We studied the safety and efficacy of treatment with continuous infusion of a von Willebrand factor (vWF) concentrate Haemate-P in patients with von Willebrand disease (vWD). Three patients with mild and 5 patients with severe forms of vWD, were treated with continuous infusion of Haemate-P by minipump. The indications for treatment were: to prevent bleeding during 9 surgical procedures or 1 vaginal delivery in 6 patients and to treat 2 bleeding episodes in 2 patients. The patients were monitored daily for factor VIII (FVIII:C) and ristocetin cofactor (vWF: RCo) levels and the infusion rate was adjusted to maintain the desired therapeutic level of vWF:RCo. The treatment was effective in preventing surgical bleeding and controlling bleeding episodes. All factor VIII:C and most of the vWF:RCo levels measured during the study period were above the target therapeutic levels. A significant decrease in clearance of FVIII:C and vWF:RCo was observed over the treatment period. Haemate-P consumption averaged 24.3+/-7.9 vWF:RCo U/kg/day which is approximately half the expected dose had intermittent bolus injections been used. We suggest that continuous Haemate-P infusion is superior to intermittent bolus injections for the treatment of vWD patients by virtue of its efficiency, simplicity and considerable savings.

Authors+Show Affiliations

Institute of Thrombosis and Hemostasis and National Haemophilia Center, Sheba Medical Center, Tel-Hashomer, Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10063997

Citation

Lubetsky, A, et al. "Safety and Efficacy of Continuous Infusion of a Combined Factor VIII-von Willebrand Factor (vWF) Concentrate (Haemate-P) in Patients With Von Willebrand Disease." Thrombosis and Haemostasis, vol. 81, no. 2, 1999, pp. 229-33.
Lubetsky A, Schulman S, Varon D, et al. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Thromb Haemost. 1999;81(2):229-33.
Lubetsky, A., Schulman, S., Varon, D., Martinowitz, U., Kenet, G., Gitel, S., & Inbal, A. (1999). Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Thrombosis and Haemostasis, 81(2), pp. 229-33.
Lubetsky A, et al. Safety and Efficacy of Continuous Infusion of a Combined Factor VIII-von Willebrand Factor (vWF) Concentrate (Haemate-P) in Patients With Von Willebrand Disease. Thromb Haemost. 1999;81(2):229-33. PubMed PMID: 10063997.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. AU - Lubetsky,A, AU - Schulman,S, AU - Varon,D, AU - Martinowitz,U, AU - Kenet,G, AU - Gitel,S, AU - Inbal,A, PY - 1999/3/4/pubmed PY - 1999/3/4/medline PY - 1999/3/4/entrez SP - 229 EP - 33 JF - Thrombosis and haemostasis JO - Thromb. Haemost. VL - 81 IS - 2 N2 - We studied the safety and efficacy of treatment with continuous infusion of a von Willebrand factor (vWF) concentrate Haemate-P in patients with von Willebrand disease (vWD). Three patients with mild and 5 patients with severe forms of vWD, were treated with continuous infusion of Haemate-P by minipump. The indications for treatment were: to prevent bleeding during 9 surgical procedures or 1 vaginal delivery in 6 patients and to treat 2 bleeding episodes in 2 patients. The patients were monitored daily for factor VIII (FVIII:C) and ristocetin cofactor (vWF: RCo) levels and the infusion rate was adjusted to maintain the desired therapeutic level of vWF:RCo. The treatment was effective in preventing surgical bleeding and controlling bleeding episodes. All factor VIII:C and most of the vWF:RCo levels measured during the study period were above the target therapeutic levels. A significant decrease in clearance of FVIII:C and vWF:RCo was observed over the treatment period. Haemate-P consumption averaged 24.3+/-7.9 vWF:RCo U/kg/day which is approximately half the expected dose had intermittent bolus injections been used. We suggest that continuous Haemate-P infusion is superior to intermittent bolus injections for the treatment of vWD patients by virtue of its efficiency, simplicity and considerable savings. SN - 0340-6245 UR - https://www.unboundmedicine.com/medline/citation/10063997/Safety_and_efficacy_of_continuous_infusion_of_a_combined_factor_VIII_von_Willebrand_factor__vWF__concentrate__Haemate_P__in_patients_with_von_Willebrand_disease_ L2 - http://www.diseaseinfosearch.org/result/7418 DB - PRIME DP - Unbound Medicine ER -